Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 837 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Watson commences US Phase III study of Esmya

Esmya is a first-in-class, orally active selective progesterone receptor modulator which reversibly blocks progesterone receptors in target tissues. The multi-center randomized double-blind US Phase 3 study included 300

Teva introduces generic Naramig

Naratriptan is a generic equivalent form of GlaxoSmithKline’s Naramig (Naratriptan Hydrochloride), indicated in the acute treatment of the headache phase of migraine attacks with or without aura. Teva